Apolipoprotein B
Apolipoprotein B (ApoB) is a protein that in humans is encoded by the gene.
≈ 5 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Apolipoprotein B (ApoB) is a protein that in humans is encoded by the gene. Its measurement is commonly used to detect the risk of atherosclerotic cardiovascular disease.
Genetic disorders
High levels of ApoB are related to heart disease. Hypobetalipoproteinemia is a genetic disorder that can be caused by a mutation in the ApoB gene, APOB. Abetalipoproteinaemia is caused by a mutation in the microsomal triglyceride transfer protein gene, MTTP. Mutations in gene APOB100 can also cause familial hypercholesterolemia, a hereditary (autosomal dominant) form of metabolic disorder hypercholesterolemia.
Regulation
The expression of APOB is regulated by cis-regulatory elements in the APOB 5′ UTR and 3′ UTR.
RNA editing
The mRNA encoding this protein is subject to cytidine to uridine (C to U) site-specific RNA editing. ApoB100 and ApoB48 are encoded by the same gene, however, the differences in the translated proteins are not due to alternative splicing but are due to the tissue-specific RNA editing event. ApoB mRNA editing was the first example of editing observed in vertebrates.
Editing of ApoB mRNA occurs in all placental mammals. Editing occurs post transcriptionally as the nascent polynucleotides do not contain edited nucleosides.
Type
C to U editing of ApoB mRNA requires an editing complex or holoenzyme (editosome) consisting of the C to U-editing enzyme Apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 (ApoBEC-1) as well as other auxiliary factors. ApoBEC-1 is a protein that in humans is encoded by the APOBEC1 gene. It is a member of the cytidine deaminase family.
ApoBEC-1 alone is not sufficient for the editing of ApoB mRNA and requires at least one of these auxiliary factors, APOBEC1 complementation factor (A1CF) for editing to occur. A1CF contains 3 non-identical repeats. It acts as the RNA-binding subunit and directs ApoBEC-1 to the ApoB mRNA downstream of the edited cytidine.
Other auxiliary factors are known to be part of the holoenzyme. Some of these proteins have been identified, these are CUG binding protein 2 (CUGBP2), SYNCRIP (glycine-arginine-tyrosine-rich RNA binding protein, GRY-RBP), heterogeneous nuclear ribonucleoprotein (hnRNP)-C1 (HNRNPC), ApoBEC-1 binding protein ABBP1 (HNRNPAB), ABBP2, KH-type splicing regulatory binding protein (KHSRP), Bcl-2-associated athanogene 4 (BAG4), and auxiliary factor (AUX)240.
All these proteins have been identified using detection assays and have all been demonstrated to interact with either ApoBEC-1, A1CF, or ApoB RNA. The function of these auxiliary proteins in the editing complex is unknown.
As well as editing ApoB mRNA, the ApoBEC-1 editsome also edits the mRNA of NF1. mRNA editing of ApoB mRNA is the best-defined example of this type of C to U RNA editing in humans.
Location
Despite being a 14,000-residue-long transcript, a single cytidine is targeted for editing. Within the ApoB mRNA, a sequence consisting of 26 nucleotides necessary for editing is found. This is known as the editing motif.
These nucleotides (6662–6687) were determined to be essential by site-specific mutagenesis experiments. An 11 nucleotide portion of this sequence 4–5 nucleotides downstream from the editing site is an important region known as the mooring sequence. A region called the spacer element is found 2–8 nucleotides between the edited nucleoside and this mooring sequence.
There is also a regulatory sequence 3′ to the editing site. The active site of ApoBEC-1, the catalytic component of the editing holoenzyme, is thought to bind to an AU-rich region of the mooring sequence with the aid of ACF in binding the complex to the mRNA. The edited cytidine residue is located at nucleotide 6666 located in exon 26 of the gene.
Editing at this site results in a codon change from a Glutamine codon (CAA) to an in-frame stop codon (UAA). Computer modelling has detected that for editing to occur, the edited Cytidine is located in a loop. The selection of the edited cytidine is also highly dependent on this secondary structure of the surrounding RNA.
There are also some indications that this loop region is formed between the mooring sequence and the 3′ regulatory region of the ApoB mRNA. The predicted secondary structure formed by ApoB mRNA is thought to allow for contact between the residue to be edited and the active site of APOBEC1, as well as for binding of ACF and other auxiliary factors associated with the editosome.
Structure
Editing results in a codon change creating an in-frame stop codon, leading to translation of a truncated protein, ApoB48. This stop codon results in the translation of a protein that lacks the carboxyl terminus, which contains the protein's LDLR binding domain. The full protein ApoB100, which has nearly 4500 amino acids, is present in VLDL and LDL.
Since many parts of ApoB100 are in an amphipathic condition, the structure of some of its domains is dependent on underlying lipid conditions. However, it is known to have the same overall folding as LDL, having five main domains. Recently the first structure of LDL at human body temperature in native condition has been found using cryo-electron microscopy at a resolution of 16 Angstrom.
The overall folding of ApoB-100 has been confirmed, and some heterogeneity in the local structure of its domains has been mapped.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1373433041 under CC BY-SA 4.0; modifications have been made.